NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

Clinical Trials 250

Clinical Trials Chronic Pain Cannabinoids Patients 250

Veriheal

AUGUST 12, 2021

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Epilepsy 68

Epilepsy Pharmaceutical Patients Sleep 68

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. The primary endpoint showed a median 16.6

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Canna Law Blog

FEBRUARY 25, 2022

If you keep a pulse on this issue, you know that for the past three years, the FDA has held the position that CBD cannot be marketed as a dietary ingredient because it was first studied and approved as a drug ingredient in GW Pharmaceuticals’ Epidiolex ( Drug Exclusion Rule ). According to NPA’s petition, the U.S.

CBD 80

CBD Safety Data Food 80

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. With medical research indicating that using the plant provides significant medical benefits, the Czech Chamber of Deputies suggested a revision to the government’s Act on pharmaceuticals.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. About RYAH Group, Inc. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

DECEMBER 2, 2021

Products that are listed as having been verified as meeting the minimum quality standards are unapproved medicines – there has been no assessment of their safety or efficacy. MW Pharma Limited t/a NUBU Pharmaceuticals. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. Sativex data sheet.

Medicine 52

Medicine Pharmaceutical Sativa THC 52

Canna Law Blog

FEBRUARY 21, 2020

Specifically, the FSA is giving the CBD industry until March 31, 2021 to submit valid novel food authorization applications to ensure these products meet specific safety standards. Following the March 31, 2021 deadline, only products for which a valid application has been submitted will be allowed to remain on the market.

Food 93

Food CBD Legalization Hemp 93

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

DECEMBER 19, 2021

Products that are listed as having been verified as meeting the minimum quality standards are unapproved medicines – there has been no assessment of their safety or efficacy. MW Pharma Limited t/a NUBU Pharmaceuticals. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. CDC Pharmaceuticals Ltd. Sativex data sheet.

Medicine 52

Medicine Pharmaceutical THC Sativa 52

MMJ Recs

NOVEMBER 17, 2023

The community impact is visible in several key areas: Healthcare Advancements MMJ has expanded the range of treatment options available to patients, offering an alternative to conventional pharmaceuticals. Over time, Maryland has refined its approach to ensure the accessibility and safety of MMJ for its residents.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Veriheal

OCTOBER 29, 2020

Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

NOVEMBER 24, 2019

Building the bridge between brands and the marketplace through testing and the importance of good data. These events, amongst other drivers, have shown the obvious need to regulate product safety in CBD and THC products in a holistic and standardized way.

Business 95

Business Data Wellness and Beauty Safety 95

Cannabis Law Report

JULY 12, 2021

Algernon Pharmaceuticals Inc. CSE: MSET) revealed additional preclinical data showing strong efficacy and improved safety in a head-to-head comparison with psilocybin. (CSE: PULL). 0.385 +0.155 (67.39%). Cybin Corp. NEO: CYBN). 3.250 +0.650 (25.00%). Numinus Wellness Inc. TSX-V: NUMI). 1.020 +0.110 (12.09%). Top Decliners.

Treatment 66

Treatment Decriminalization Pharmaceutical Data 66

Cannabis Law Report

JUNE 7, 2019

The use of pharmaceutical cannabinoid products in Singapore comes under strict frameworks and regulations and does not diminish the country’s zero-tolerance position against drugs, the Home Affairs and Health ministries have said. The Straits Times Reports. Cannabinoids are chemical compounds found in the cannabis plant.

Pharmaceutical 40

Pharmaceutical Cannabinoids Safety Data 40

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

Cannabis Law Report

SEPTEMBER 20, 2021

The products leverage pharmaceutical technology to maximize performance and safety. Additional CB4 products from the Opticann suite of branded products will be launched in the upcoming weeks, including CB4 Derma skin cream and CB4 Clear face gel skincare products uniquely backed by product specific clinical trial data.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

SEPTEMBER 7, 2021

Despite these considerations, HHC vape carts hit the market without an accredited Certificate of Analysis (COA) or toxicity data. The synthetic cannabinoid blend — Spice — is comprised of beta-HHC derivatives the pharmaceutical giant in the 80s. Old data suggests that beta-HHC is 1000% more potent than D9-THC. Show your work.

THC 93

THC Cannabinoids Digestion Data 93

Cannabis Law Report

JUNE 9, 2022

11:00-12:00 PM: Interstate Commerce: Impacts on markets, licensing, and consumer safety. 3:15-4:15 PM: Preventing Youth Access, Promoting Consumer Safety, & Protecting Public Health in State Markets. Panelists: Darrin Grondel, EdD, Vice President of Traffic Safety & Government Relations, Responsibility.org.

Policy 52

Policy Safety Seed-To-Sale Data 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

OCTOBER 21, 2021

adults shows broad support for securely labeling cannabis products to verify their legitimacy and safety in the marketplace. Ensuring the safety of cannabis products is top of mind for Americans.

Safety 52

Safety Research and Development Compliance Compliance 52

Cannabis Law Report

AUGUST 23, 2021

After confirmation of 6-months stability of tech-transfer batch, the work has been initiated, with preliminary data packages available by the second half of September, well within the proposed timelines. . & Notice of 2021 Final Results. . Since the year-end, the £2.6

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

JUNE 16, 2021

This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. Training will be provided within the research program for licensed practitioners to assess the safety of psychedelic medicines and to classify and report positive and adverse events.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. These can be administered through pharmaceutical products such as oral solutions and sprays.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

AUGUST 16, 2021

It is also a tool used to “determine the nature and scope of child abuse and neglect” and compare Arizona data to national trends, regardless of whether that neglect or abuse arose from the lawful or unlawful use of substances, a mental illness or incapacity, or simply an inability to properly care for a child. 600 USD raised of $400 goal.

Safety 116

Safety Patients Cannabis Law 116

WeedAdvisor

JULY 21, 2019

South America needs safe, reliable growing materials, cannot use certain pesticides, needs to meet cleanliness and safety standards, etc. The production of pharmaceutical-grade cannabis is a highly specialised process — it is not as simple as planting a few marijuana seeds, harvesting the crop and turning it into medicine.”.

Conditions 60

Conditions Seed-To-Sale Compliance Compliance 60

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland.

History 52

History Clinical Trials Legalization Research and Development 52